120 related articles for article (PubMed ID: 18672285)
21. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
[TBL] [Abstract][Full Text] [Related]
22. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome.
Bouaziz JD; Remtoula N; Bensussan A; Marie-Cardine A; Bagot M
Br J Dermatol; 2010 Jan; 162(1):123-8. PubMed ID: 19681856
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic identification of Sezary cells in peripheral blood.
Bogen SA; Pelley D; Charif M; McCusker M; Koh H; Foss F; Garifallou M; Arkin C; Zucker-Franklin D
Am J Clin Pathol; 1996 Dec; 106(6):739-48. PubMed ID: 8980349
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
[TBL] [Abstract][Full Text] [Related]
25. The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.
Scala E; Abeni D; Pomponi D; Narducci MG; Lombardo GA; Mari A; Frontani M; Picchio MC; Pilla MA; Caprini E; Russo G
Haematologica; 2010 Nov; 95(11):1905-12. PubMed ID: 20663947
[TBL] [Abstract][Full Text] [Related]
26. CD4
Vonderheid EC; Hou JS
Leuk Lymphoma; 2018 Feb; 59(2):330-339. PubMed ID: 28595473
[TBL] [Abstract][Full Text] [Related]
27. CD7 expression in reactive and malignant human skin T-lymphocytes.
Alaibac M; Pigozzi B; Belloni-Fortina A; Michelotto A; Saponeri A; Peserico A
Anticancer Res; 2003; 23(3B):2707-10. PubMed ID: 12894562
[TBL] [Abstract][Full Text] [Related]
28. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma.
Vonderheid EC; Boselli CM; Conroy M; Casaus L; Espinoza LC; Venkataramani P; Bigler RD; Hou JS
J Invest Dermatol; 2005 Mar; 124(3):651-61. PubMed ID: 15737208
[TBL] [Abstract][Full Text] [Related]
29. Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells.
Koh HS; Lee C; Lee KS; Park EJ; Seong RH; Hong S; Jeon SH
Mol Cells; 2009 Dec; 28(6):553-8. PubMed ID: 19937140
[TBL] [Abstract][Full Text] [Related]
30. [Peripheral blood Sézary cells and the diagnosis of Sézary syndrome].
Tessier-Marteau A; Le Corre Y; Gérard J; Avenel-Audran M; Geneviève F; Verret JL; Zandecki M
Ann Biol Clin (Paris); 2008; 66(4):447-53. PubMed ID: 18725348
[TBL] [Abstract][Full Text] [Related]
31. On the diagnosis of erythrodermic cutaneous T-cell lymphoma.
Vonderheid EC
J Cutan Pathol; 2006 Feb; 33 Suppl 1():27-42. PubMed ID: 16412210
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.
Boonk SE; Zoutman WH; Marie-Cardine A; van der Fits L; Out-Luiting JJ; Mitchell TJ; Tosi I; Morris SL; Moriarty B; Booken N; Felcht M; Quaglino P; Ponti R; Barberio E; Ram-Wolff C; Jäntti K; Ranki A; Bernengo MG; Klemke CD; Bensussan A; Michel L; Whittaker S; Bagot M; Tensen CP; Willemze R; Vermeer MH
J Invest Dermatol; 2016 Jul; 136(7):1364-1372. PubMed ID: 26930587
[TBL] [Abstract][Full Text] [Related]
33. Follow-up of the T-cell clonality in Sezary patients treated by extracorporeal photopheresis using a new assay: the immunoscope technique.
Ingen-Housz-Oro S; Bussel A; Flageul B; Dubertret L; Michel L; Gachelin G; Kourilsky P; Bachelez H; Musette P
Transfus Apher Sci; 2003 Feb; 28(1):35-42. PubMed ID: 12620267
[TBL] [Abstract][Full Text] [Related]
34. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
35. Structure and function of the CD7 molecule.
Sempowski GD; Lee DM; Kaufman RE; Haynes BF
Crit Rev Immunol; 1999; 19(4):331-48. PubMed ID: 10530432
[TBL] [Abstract][Full Text] [Related]
36. Interaction between the extracellular domain of CD7 and concanavalin A: a clue to the identity of the ligand for CD7.
Leta E; Hou Z; Lederman L; Jung LK
Cell Immunol; 1996 Oct; 173(1):15-21. PubMed ID: 8871597
[No Abstract] [Full Text] [Related]
37. A new monoclonal antibody (CH-F42) recognizes a CD7- subset of normal T lymphocytes and circulating malignant cells in adult T-cell lymphoma-leukemia and Sézary syndrome.
Labastide WB; Rana MT; Barker CR
Blood; 1990 Oct; 76(7):1361-8. PubMed ID: 1698478
[TBL] [Abstract][Full Text] [Related]
38. [Sezary syndrome with serum monoclonal immunoglobulin. Absence of detectable shared idiotype between the monoclonal immunoglobulin and membrane structures of the Sezary cells (author's transl)].
Preud'homme JL; Sohier J; Danon F
Nouv Presse Med; 1980 Mar; 9(17):1215-7. PubMed ID: 7005868
[TBL] [Abstract][Full Text] [Related]
39. A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.
Hoffmann JC; Atwater SK; Hong E; Kumar J; Khodadoust M; Kim Y; Ohgami RS
Am J Dermatopathol; 2020 Jun; 42(6):389-396. PubMed ID: 32433315
[TBL] [Abstract][Full Text] [Related]
40. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma.
Liu TY; Chen CY; Tien HF; Lin CW
Histopathology; 2009 Jan; 54(2):214-20. PubMed ID: 19207946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
